Table 1 lists the transduced cell types and YL-2 doses administered for eachinjection. IL-2 secretion by 
the transduced cells in vitro was measured by an enzyme linked immunosorbent assay (ELISA). Tumor 
cells transduced with DC/AD/R/IL-2 and GlNaCvi2.23 were found to express similar amounts of IL-2 in 
vitro (10-43 units EL-2/10^ cells/24 hrs). However, fibroblasts transduced with the GlNaCvi2.23 vector 
secreted approximately 5 to 10 fold higher levels of IL-2 compared to those transduced with the 
DC/AD/R/IL-2 vector (Table 1). The total administered IL-2 dose ranged from 3 to 440 units/24 hrs. 
The total tumor cell dose for each injection was 10^ cells. 
Table 1 IL-2 GENE THERAPY OF GLIOBLASTOMA 
TREATMENT SUMMARY 
Date of 
Immunization 
Rx# 
Retroviral 
Vector 
Transduced 
Cell Type 
# of 
Transduced 
Cells 
IL-2 Secretion 
10^ cells/24 hr 
Total 
Dose of IL-2 
1/4/93 Rx # 1 
DC/AD/R/IL-2 
tumor 
1.25 X 10^ 
43 units 
5 units 
1/27/93 Rx # 2 
DC/AD/R/IL-2 
tumor 
2.60 X 105 
10 units 
3 units 
2/19/93 Rx#3 
DC/AD/R/IL-2 
fibroblast 
4.60 X 105 
40 units 
18 units 
3/5/93 Rx U4 
DC/AD/R/IL-2 
fibroblast 
4.20 X 10^ 
51 units 
21 units 
3/26/93 Rx#5 
DC/AD/R/EL-2 
fibroblast 
2.25 X 10^ 
35 units 
8 units 
4/16/93 Rx#6 
DC/AD/R/IL-2 
fibroblast 
1.20 X 10^ 
91 units 
11 units 
5/12/93 Rx#7 
GlNaCvi2.23 
fibroblast 
2.50 X 105 
427 units 
107 units 
5/27/93 Rx#8 
GlNaCvi2.23 
fibroblast 
3.20 X 10^ 
328 units 
125 units 
tumor 
2.00 X 10<> 
10 units 
6/11/93 Rx#9 
GlNaCvi2.23 
fibroblast 
2.00 X 10^ 
550 units 
440 units 
tumor 
1.00 X 10^ 
33 units 
9/17/93 Rx#10 
GlNaCvi2.23 
fibroblast 
4.40x 10=> 
135units 
112 units 
tumor 
2.90 X 10<> 
18 units 
Recombinant DNA Research, Volume 19 
[619] 
